Combined MSC and GLP-1 Therapy Modulates Collagen Remodeling and Apoptosis following Myocardial Infarction by Wright, Elizabeth J et al.
Syddansk Universitet
Combined MSC and GLP-1 Therapy Modulates Collagen Remodeling and Apoptosis
following Myocardial Infarction
Wright, Elizabeth J; Hodson, Nigel W.; Sherratt, Michael J.; Kassem, Moustapha; Lewis,
Andrew L; Wallrapp, Christine; Malik, Nadim; Holt, Cathy M
Published in:
Stem Cells International
DOI:
10.1155/2016/7357096
Publication date:
2016
Document version
Final published version
Document license
CC BY
Citation for pulished version (APA):
Wright, E. J., Hodson, N. W., Sherratt, M. J., Kassem, M., Lewis, A. L., Wallrapp, C., ... Holt, C. M. (2016).
Combined MSC and GLP-1 Therapy Modulates Collagen Remodeling and Apoptosis following Myocardial
Infarction. Stem Cells International, 2016, [7357096]. DOI: 10.1155/2016/7357096
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 19. Apr. 2017
Research Article
Combined MSC and GLP-1 Therapy Modulates Collagen
Remodeling and Apoptosis following Myocardial Infarction
Elizabeth J. Wright,1 Nigel W. Hodson,2 Michael J. Sherratt,2 Moustapha Kassem,3
Andrew L. Lewis,4 ChristineWallrapp,5 NadimMalik,1 and Cathy M. Holt1
1Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9NT, UK
2Division of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health,
University of Manchester, Manchester M13 9NT, UK
3KMEB, Department of Endocrinology and Metabolism, University of Southern Denmark, 5000 Odense, Denmark
4Biocompatibles UK Ltd, Chapman House, Farnham GU9 8QL, UK
5CellMed AG, Industriestrasse 19, Alzenau, Germany
Correspondence should be addressed to Cathy M. Holt; cathy.holt@manchester.ac.uk
Received 14 June 2016; Revised 29 September 2016; Accepted 19 October 2016
Academic Editor: Jia-Qiang He
Copyright © 2016 Elizabeth J. Wright et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. Mesenchymal stem cells (MSCs) and glucagon-like peptide-1 (GLP-1) are being tested as treatment strategies for
myocardial infarction (MI); however, their mechanisms in the heart are not fully understood. Methods. We examined the effects
of MSCs, either native, or engineered to secrete a GLP-1 fusion protein (MSCs ± GLP-1), on human cardiomyocyte apoptosis in
vitro. The effect on cardiac remodeling when encapsulated in alginate beads (CellBeads-MSC and CellBeads-MSC + GLP-1) was
also evaluated in a pig MI model, whereby pigs were treated with Empty Beads, CellBeads-MSC, or CellBeads-MSC + GLP-1 and
sacrificed at one or four weeks following MI. Results. MSC + GLP-1 conditioned media demonstrated antiapoptotic effects on
ischaemic human cardiomyocytes in vitro. In vivo, qRT-PCR revealed large changes in the expression of several genes involved
in extracellular matrix remodeling, which were altered following MSC ± GLP treatment. After four weeks, infarcted areas were
imaged using atomic force microscopy, demonstrating significant alterations between groups in the structure of collagen fibrils and
resulting scar. Conclusions. These data demonstrate that MSCs ± GLP-1 exhibit modulatory effects on healing post-MI, affecting
both apoptosis and collagen scar formation. These data support the premise that both MSCs and GLP-1 could be beneficial in MI
treatment.
1. Introduction
Myocardial infarction (MI) is one of the leading causes of
death in the developed world. Although advancements in
the treatment for MI have led to improved survival rates,
this has also led to an increase in the incidence of heart
failure [1]. The extent of ischaemia-induced apoptosis of
cardiomyocytes determines the size of the infarct, which
is a key indicator of both survival and the degree of left
ventricular remodeling and therefore function after MI [1].
The majority of myocardial cell death occurs in the first 24
hours after the insult [2]; therefore inhibiting cell death at an
early stage is crucial to limiting the degree of remodeling and
improving prognosis.
After the initial cell death in the infarct, collagen is
deposited, which is crucial for maintaining the structure of
the heart and preventing cardiac rupture [3]. The properties
of the scar are extremely important; a thick, dense scar can
result in arrhythmias, whereas a thin, disorganized scar can
result in rupture [4]. Scar formation is a highly complex
and regulated process; modulation of remodeling could,
therefore, be beneficial for healing following MI. Collagen
levels are tightly regulated by the opposing actions of matrix
metalloproteinases (MMPs) which break down collagen and
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tissue inhibitors of metalloproteinases (TIMPs) which inhibit
MMPs. MMPs are activated within ten minutes of coronary
occlusion [5] rapidly degrading extracellular matrix. MMP
activity is enhanced in the presence of cytokines such as TNF
[6].
Current therapies for treatment of MI aim to restore
blood supply and to reduce apoptosis in the infarcted area.
One antiapoptotic agent that has demonstrated a clinical
benefit by controlling the spread of the ensuing cell death is
glucagon-like peptide-1 (GLP-1), a natural gut incretin hor-
mone, which regulates blood glucose homeostasis [7]. GLP-
1 and its more stable analogue Exendin-4 (Exenatide) have
both demonstrated cardioprotective properties following
myocardial infarction (MI) in a number of animal and human
studies [8–13]. Administration of theGLP-1 analogue Liraglu-
tide similarly showed cardioprotective benefits following MI,
reducing caspase-3 activation via the GLP-1R in a mouse
model [14].
Another promising treatment option followingMI is stem
cell therapy. Although originally intended to directly replace
the damaged cells within the compromisedmyocardium, it is
now widely accepted that stem cells exert their beneficial
effects largely via paracrine secretion of cardioprotective
factors [15–17]. Initial outcomes from stem cell trials in the
hearts of both animals and humans were promising; however,
more recent clinical trial results have shown mixed results
[18–20]. Increasingly, MSCs are being modified to enhance
their cardioprotective effects through overexpression of key
proteins and factors [21–25].
Previous work from our group has demonstrated the
cardioprotective effects ofMSCs engineered to secrete a GLP-
1 fusion protein (CellBead) in a porcine model of MI [26,
27]. The fusion protein comprises of two GLP-1 molecules
adjoined by an intervening peptide, which has the same
action as GLP-1 but with an increased resistance to enzymatic
breakdown by the enzyme dipeptidylpeptidase-IV (DPP-IV)
and thus a longer half-life in vivo. These MSCs are also
known to secrete a number of other potent cardioprotective
factors including vascular endothelial growth factor (VEGF),
monocyte chemoattractant protein-1 (MCP-1), interleukin-
6 (IL-6), and interleukin-8 (IL-8) [25], resulting in a novel,
combined therapy of GLP-1 and paracrine MSC factors.
We previously demonstrated that MSC + GLP-1 treat-
ment following MI had a functional benefit by significantly
reducing infarct size four weeks afterMI as well as improving
cardiac function determined by improved ejection fraction
[26]. The benefit was shown to be a result of multiple
differentmechanisms andwe partially attributed the decrease
in infarct size to the known antiapoptotic action of the GLP-
1 analogue released locally into the infarct zone from the
CellBeads. However, there were no significant changes in
apoptosis levels between treatment and control groups one
week after MI, suggesting that inhibition of apoptosis may
occur at a much earlier time point. MSC + GLP-1 treatment
also resulted in a significant increase in collagen in infarcted
areas; however the underlyingmechanisms occurring remain
unknown, as is whether this effect is either beneficial or
detrimental to the healing process.
The aims of the present study were to further characterize
the efficacy of MSC and MSC + GLP-1 treatment in promot-
ing healing and remodeling following MI and the causative
mechanisms of action, using both an in vitro ischaemiamodel
and a pig embolizationmodel ofMI. In order to achieve these
aims, we tested the hypothesis that MSCs, either alone or
modified to release GLP-1, would
(1) decrease apoptosis of ischaemic human cardiomy-
ocytes in vitro;
(2) alter ECM turnover by influencing the expression of
key structural proteins and proteases, which in turn
would affect structural remodeling by influencing the
macromolecular architecture of fibrillar collagens.
2. Materials and Methods
2.1. GLP-1 CellBead Production. Primary human mesenchy-
mal stem cells (hMSCs) were obtained from the bonemarrow
of a healthy, male, 33-year-old donor following informed
consent. This procedure was carried out with full ethics
approval [28]. The MSCs were immortalized to form a cell
line, following stable transduction by a retroviral vector
containing human telomerase reverse transcriptase (hTERT),
as previously described [28]. Cells were modified to secrete a
fusion protein of GLP-1, known as CM1, which exhibits an
extended half-life in vivo [29]. The cells were then entrapped
in alginate beads using a double encapsulation process with
ionic crosslinking that can be used to make CellBeads of a
minimum 160 𝜇m and up to a maximum 600 𝜇m in diameter
(limited by diffusion of nutrients to the core) depending upon
their intended use. In this study, we usedCellBeads of 600 𝜇m
in diameter, consisting of a core of around 3000 cells/bead
surrounded by a 20𝜇m cell-free alginate barrier for immune-
protection, as the intention was to administer the beads to
induce a coronary infarct. This size of beads is sufficient to
lodge in smaller coronary vessels and produce microinfarcts
using previously describedmethods [30].The amount of CM1
and paracrine factors (VEGF,MCP-1, IL-1, and IL-6), released
from the CellBeads, was previously quantified using ELISA as
described earlier [25].
2.2. In Vitro Human Cardiomyocyte Ischaemia-Reperfusion
Model. To generate conditioned medium (MEM, 31095,
Gibco), cells with (MSC + GLP-1) and without (MSC) GLP-1
expression were cultured for 48 hours (confluent in T25 flask
containing 5mL media), with media replaced after 24 hours.
Media were supplemented with L-tyrosine and 10% FCS.
Cells were cultured at 37∘C with 5% CO
2
. Ischaemic car-
diomyocyte apoptosis and viability were then quantified for
cells exposed to conditioned media (MSC ± GLP-1), normal
MEM media, the GLP-1 analogue Exendin-4 (Ex-4,1933,
Tocris Bioscience), and endogenous human GLP-1 (G-9416,
Sigma Aldrich).
Adult human primary cardiomyocytes (hCMs) were pur-
chased from Promocell (C-12811) and cultured in specialized
myocyte growth medium with supplement mix (C-22270
and C-39275, Promocell). Cells were acquired from donors
with informed, written consent and in compliance with
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Table 1: Sequences of forward and reverse primers used for qRT-PCR.
Gene Sense primer Antisense primer Product length
MMP2 TTCGACAAGGATGGCAAGTAC GGAAGCGGAACGGGAACT 100
MMP9 CTTGGTCCTGGTGCTCCT ATAAGATTGGTTCGTAGGTCTCC 99
TIMP1 AGCCGAAACCTGCACAGT CACGAGGTTCTTTATTTCATCATCT 80
TIMP2 GCAATGCAGACGTAGTGATC TCCGTTTGATGGGGTTGC 90
TGFB1 ACTGGGTCTCCGTGTGTTG ACAAATGAATGGTGGACAGACA 111
COL1A1 ACGGCCTCAGGTACCATGAC GCTGGGACAGTTCTTGATTTCG 122
COL3A1 TCCCCAAGGTGTCAAAGGT GTTACCGTTACTGCCAGGAG 103
appropriate ethical approval. Ventricular cells were pooled
from female Caucasian donors aged 31 and 51 years. These
myocytes were confirmed as immunopositive for sarcomeric
alpha-actinin, GATA-4, and slow muscle myosin and were
negative for CD90, confirming their phenotype; the cells,
however, do not contract (Promocell, Germany). Myocytes
were used for assays between passages 4–7.
An adapted form of the ischaemic pellet method was
used, which has been described previously [31, 32]. Cells from
two confluent T150 flasks were enzyme dispersed, collected
into a falcon tube and centrifuged at 1,200 r.p.m for five min-
utes to form a pellet. Supernatant was removed and a layer of
mineral oil (M5310, Sigma Aldrich) was added to prevent
oxygen exchange. The cells were then incubated at 37∘C for
one hour, resulting in ischaemia. The cells were resuspended
in media and seeded at a density of 135,000 cells/mL in
a 24-well plate for a trypan blue viability assay or an
eight-chamber culture slide for subsequent TUNEL stain-
ing. Immediately after seeding, human cardiomyocytes were
exposed to either Basal media, MSC conditioned media
(MSC-m), MSC + GLP-1 conditioned media (MSC + GLP-
1m), media + Exendin-4 (Ex-4), or media + GLP-1 (GLP-1).
All peptides were used at a final concentration of 100 nM.
Apoptosis was measured after 24 hours using TUNEL
staining, according to the manufacturer’s instructions
(G3250, Promega). Cells were mounted with Vectashield
containing DAPI (H-1500, Vector) and examined under
fluorescent light. With the observer blinded to the
experimental conditions, three random fields of view were
counted using a ×10 objective and apoptotic cells were
expressed as a percentage of total cell number (𝑛 = 8 per
condition). After 48 hours of incubation, cells were detached
with trypsin and then incubated with trypan blue (T8154,
Sigma Aldrich). The percentage of dying cells (blue stained)
and total cell number, representing viability, were counted
using a standard haemocytometer (𝑛 = 4).
2.3. Pig Embolization Model of Myocardial Infarction.
Myocardial infarctionwas induced in female YorkshireWhite
pigs using a bead embolization model, as previously
described [30]. The left anterior descending coronary artery
branches were embolized using either empty alginate beads
(Beads), alginate beads containing immortalized human
mesenchymal stem cells (CellBeads-MSC), or beads con-
taining MSCs engineered to secrete glucagon-like peptide-1
(CellBeads-MSC + GLP-1), also as previously described [26].
MI was confirmed using echocardiography and ECG. Pigs
were allowed to recover and sacrificed at one week or four
weeks after intervention (𝑛 = 3–5 per group). Tissue was
collected and either stored in RNAlater solution (Sigma
Aldrich) for qRT-PCR analysis or fixed in paraformaldehyde
for subsequent tissue processing embedding in paraffin wax
prior to sectioning for histology and AFM.
2.4. Quantification of mRNA Expression of Genes Involved in
ECM Remodeling in Porcine Myocardium. RNA was isolated
from porcine tissue removed one week and four weeks after
MI. Tissue was taken from three distinct areas: infarct,
border, and remote, where border is the tissue immediately
surrounding the infarct and remote tissue is healthily distinct
from the infarcted area. RNAwas converted into cDNAusing
a high capacity RNA to cDNA kit (Applied Biosystems). The
cDNAwas amplified using a SYBR greenmastermix (Applied
Biosystems) and the reaction quantified using a 7900 HT fast
real time PCR system (Applied Biosystems), with the
sequence: 50∘C for two minutes followed by 95∘C for 10 min-
utes; this was then followed by 40 cycles of 15 seconds at 95∘C
and one minute at 60∘C. For dissociation, the samples were
then heated to 95∘C for 15 seconds and 60∘C for 15 seconds.
Data was analysed using the Pfaffl method, which allows for
comparison of primers with different amplification efficien-
cies. Efficiencies were calculated using LinRegPCR software
with any samples having an amplification efficiency of zero
or more than 2.2 being excluded.
The mRNA of the following genes was quantified: TGF-
𝛽1, TIMP1, TIMP2, MMP2, MMP9, collagen I (Col1a1), and
collagen III (Col3a1) and 18S was used as a housekeeping
gene (selected using a geNorm kit from Primer Design). All
primers were custom made by Primer Design, UK, with the
sequences shown in Table 1.
2.5. Analysis of Collagen Fibril Orientation and Macromolec-
ular Structure in Porcine Myocardium Using Atomic Force
Microscopy. Paraffin wax-embedded infarcted porcine ven-
tricular tissue was classified as either infarct, border, or
remote tissue based onH&E staining, as previously described
[26]. Serial sections (7𝜇m) were cut and mounted on poly-
L-lysine coated slides. Sections were dewaxed in xylene,
rehydrated through a graded alcohol series, and washed in
distilled water for five minutes. Sections were left to air dry
before AFM analysis. Areas of interest were identified by
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Figure 1: Effect of GLP-1 CellBeads on apoptosis and viability of ischaemic human cardiomyocytes. (a) Apoptosis was assessed using TUNEL
staining. Scale bar = 50 𝜇m. (b) 24 hours after ischaemia, MSC-GLP-1 conditioned media significantly reduced apoptosis compared to media
alone. GLP-1, Exendin -4, and MSC media showed no significant reduction in apoptosis as assessed by TUNEL. (c) Cardiomyocyte viability
was determined using trypan blue dye exclusion assay. GLP-1, MSC conditioned media, and MSC-GLP-1 conditioned media improved cell
viability compared to media alone, 48 hours after ischaemia. (d) Ischaemic cell viability determined by cell number was increased with all
agonists, compared with media alone; however this was not significant.𝑁 = 4 per group ∗𝑃 < 0.05 versus media alone.
staining adjacent sections with picrosirius red for one hour
before examination under polarized light [33].
Areas that were identified as collagen rich from the
picrosirius red staining were imaged using intermittent con-
tactmode in air using a Bruker Bioscope Catalyst AFMwith a
Nanoscope V Controller, mounted on a Nikon Eclipse Ti-I
optical microscope. Imaging was performed using Olympus
high aspect ratio etched silicon probes (OTESPA) with nom-
inal spring constant of 42N/m (Bruker, AXS, Cambridge,
UK). The instrument was periodically calibrated using a
grating with 180 nm deep 10mm2 depressions. Height and
amplitude data was recorded for 10 × 10 𝜇m scans for each
animal in each group (Beads, Beads-MSC, and Beads-MSC +
GLP-1) with 3–5 animals per group.
Individual collagen fibrils and fibril bundles were visual-
ized in 3D surface representations generated from the height
data using WSxM 4.0 software [34]. Mean fibril periodicity
was calculated from the fundamental frequency of the power
spectral density distribution in amplitude images determined
byWSxM software [35].The inclusion criteria for a fibril were
clear D-periods, a minimum length of 800 nm, and a clear
fundamental frequency peak in the power spectral density
plot. In this way, 15 fibrils weremeasured per animal (𝑛 = 3–5
per group, equating to a mean population size of 45–75 fibrils
per group). Fibril diameter was measured by drawing a line
across each individual fibril. The organization of the collagen
was measured qualitatively by examining the 3D structures
formed and the alignment of the fibrils.
2.6. Statistical Analysis. ANOVA with Bonferroni post hoc
analysis was used to test for differences between treatment
groups performed in pigs. ANOVA with Dunnett’s 𝑡-test
was used to test for differences between different treatment
groups and control in the in vitro experiments. All data are
expressed as means ± SEM. Statistical significance is denoted
as follows: ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01.
3. Results
3.1. MSC + GLP-1 Conditioned Media Have a Beneficial Effect
on Viability of Ischaemic Adult Human Cardiomyocytes In
Vitro. TUNEL analysis (Figure 1(a)) demonstrated that at
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Figure 2: Quantification of collagen I and collagen III mRNA levels. No significant differences were observed between collagen I (a) and
collagen III (b) mRNA levels within myocardium from infarct, border, and remote zones at one week after MI. At four weeks after MI, large
increases in collagen I (c) and collagen III (d)mRNA levels were observed in the Empty Bead group in both infarct and border regions and this
was significantly higher than the CellBead-MSC and CellBead-MSC + GLP-1 treated groups for collagen III.𝑁 = 3–5 per group; 𝑃 < 0.01.
24 hours after ischaemia MSC + GLP-1 conditioned media
significantly reduced the number of apoptotic cells compared
to media alone (media: 6.14 ± 0.48%; GLP-1: 3.96 ± 0.56%;
Ex-4: 5.1 ± 1.22%; MSC media: 3.71 ± 0.56%; MSC + GLP-1
media: 2.97 ± 0.4%, 𝑃 < 0.05, Figure 1(b)). At 48 hours after
ischaemia, all agonists apart from Exendin-4 reduced the
total number of dead cells, as identified by trypan blue
staining, compared to media alone (media: 19.05 ± 6.80%,
GLP-1: 5.05 ± 0.54%, Ex-4: 7.88 ± 0.39%, MSC media: 5.41 ±
0.39%, and MSC + GLP-1 media: 2.58 ± 1.65%, 𝑃 < 0.05;
Figure 1(c)). Although there was a trend towards increased
cell viability (measured as total live cell number) after
exposure to all agonists (Figure 1(d)), no significant differ-
ences were observed.
3.2. Collagen and TIMP Are Upregulated after MI and This
Is Modulated following CellBead-MSC and CellBead-MSC +
GLP-1 Treatment. At one week after MI, although increases
inmRNA expressionwere observed in all the genes examined
in the infarct zone of the Beads-MSC treated group, none
of these differences were significant. At four weeks after MI,
however, increases in expression of collagen III (Figure 2)
TIMP1, and TIMP 2 (Figure 3) were observed in the Beads
treated group compared to CellBead-MSC and CellBead-
MSC + GLP-1 treated groups; that is, the treatment caused
a significant reduction in collagen 3 and TIMP1 mRNA levels
four weeks after MI. No differences in collagen and TIMPs
mRNA expression were observed following treatment in the
remote regions (i.e., distinct from the infarct). Differences in
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Figure 3: Quantification of TIMP1 and TIMP2 mRNA levels. (a) One week after MI, small increases in TIMP1 mRNA levels were observed.
(c) After four weeks, significant increases were seen in both infarct and border regions of the Empty Bead group. (b) After one week, no
significant differences were observed in TIMP2 mRNA levels; however four weeks after MI, significantly more mRNA was detected in the
infarct and border zone of the Beads group (d).𝑁 = 3–5 per group; 𝑃 < 0.05.
expression are demonstrated in Tables 2 and 3. No signifi-
cant differences were observed between MMP2 and MMP9
mRNA levels within myocardium from infarct, border, and
remote zones one week after MI. At four weeks after MI,
increases in MMP2 and MMP9 mRNA levels were observed
in the Empty Bead group in both infarct and border regions
of pig heart after myocardial infarction.𝑁 = 3–5 per group;
however these differences were not significant (Figure 4).
3.3. TGF-𝛽 Is Increased in the Border Zone after MI and This
Is Modulated following CellBead-MSC and CellBead-MSC +
GLP Treatment. At one week after MI, TGF-𝛽MRNA levels
were slightly increased over control in all groups; however,
by 4 weeks after MI, a significant increase was observed
in the border zone myocardium; this increase was not
observed in either the CellBead-MSC or CellBead-MSC +
GLP-1 treatment groups (Figure 5). No differences in TGF-𝛽
mRNA expression were observed following treatment in the
remote regions (i.e., distinct from the infarct). Differences in
expression are demonstrated in Tables 2 and 3.
3.4.MSCTreatment Alters Collagen Scar Structure FourWeeks
after MI. AFM imaging of dewaxed ventricular biopsies
revealed detailed structural information about the collagen
fibrils, with individual D-periods clearly visible (Figures
6(a)–6(c)) and profound changes in fibrillar architecture evi-
dent between the Beads and CellBead-MSC treated groups.
The Beads treated group is comprised of many thin unor-
ganized fibrils, whereas the group treated with CellBead-
MSC displayed thicker fibrils organized into fibre bundles.
Stem Cells International 7
Table 2: Changes in expression levels of genes involved in ECM remodeling one week afterMI. Large changes in expression are demonstrated
by arrows (↑ = 2–20x increase, ↑↑ = 20–50x increase.
Gene name Beads Beads-MSC Beads-MSC-GLP-1
Infarct Border Remote Infarct Border Remote Infarct Border Remote
Col1a1 ↑ ↑ ↑ ↑ ↑ ↑
Col3a1 ↑
TIMP1 ↑ ↑ ↑ ↑
TIMP2 ↑ ↑ ↑↑ ↑ ↑
MMP2 ↑ ↑ ↑
MMP9 ↓ ↑↑ ↓↓ ↓ ↓ ↑
TGF-𝛽 ↑ ↑
Table 3: Changes in expression levels of genes involved in ECM remodeling four week afterMI. Large changes in expression are demonstrated
by arrows (↑ = 2–20x increase, ↑↑ = 20–50x increase, and ↑↑↑ = >50x change). Significance is denoted in brackets.
Gene name Beads Beads-MSC Beads-MSC-GLP-1
Infarct Border Remote Infarct Border Remote Infarct Border Remote
Col1a1 ↑↑↑ ↑↑↑ ↑ ↑ ↑↑ ↑↑ ↑
Col3a1 ↑↑ (∗∗) ↑ ↑ ↑
TIMP1 ↑ (∗) ↑ (∗) ↑ ↑ ↑ ↑ ↑
TIMP2 ↑ ↑ (∗) ↑ ↑ ↑ ↑
MMP2 ↑↑↑ ↑↑↑ ↑↑ ↑ ↑
MMP9 ↑↑↑ ↑↑↑ ↑↑ ↑ ↑ ↓
TGF-𝛽 ↑↑↑ ↑↑↑ (∗) ↑↑ ↑ ↑
The CellBead-MSC treated group displayed the most highly
organized structure, in terms of alignment and formation of
bundles, with the CellBead-MSC + GLP-1 groups showing
less organization
Collagen fibril periodicity represents the structure of the
fibril. The helical arrangement of the collagen molecules in
the fibril creates overlapping bands of polar and nonpolar
regions, with the distance between the bands being the
D-period. Periodicity was significantly increased in both
CellBead-MSC and CellBead-MSC + GLP-1 treated groups
(62.15±0.59 nmversus 64.82±0.85 nmversus 65.59±1.64 nm;
𝑃 < 0.05; Figure 6(d)). Fibril thickness/diameter gives an
indication of maturity and stability of a collagen scar. Fibril
diameter demonstrated a similar trend, with an increase
shown in the CellBead-MSC and CellBead-MSC + GLP-1
treated groups compared to the Bead group (62.07 ± 1 nm
versus 75.93 ± 4.99 nm versus 66.41 ± 3.17 nm; Figure 6(e)).
4. Discussion
Progression to heart failure from myocardial infarction
remains a huge problem in the developed world. GLP-1 elut-
ing CellBeads provide a novel therapeutic approach designed
to modulate the healing response by localized delivery of
cardioprotective factors and have previously been shown to
reduce infarct size and improve ventricular functioning in a
pig model [26].
In this study, media conditioned with MSCs engineered
to secrete GLP-1 significantly reduced apoptosis 24 hours
after ischaemia in adult human primary cardiomyocytes.The
effect was greater than either GLP-1 or MSC conditioned
media alone, indicating a synergistic combined role in pro-
moting cell survival. GLP-1 has been shown to exert antiapop-
totic effects on isolated cardiomyocytes [36, 37]; however the
effect of GLP-1 or MSC conditioned media on adult human
cardiomyocytes has not previously been examined. In addi-
tion, by 48 hours after ischaemia, all agonists had significantly
reduced total cardiomyocyte death and improved viability
compared to media alone. This suggests that GLP-1 exerts its
antiapoptotic effects in the early stages following ischaemia
and therefore rapid treatment after infarct is required in
order to limit infarct expansion. Experiments performed in a
pig model of MI have previously demonstrated the beneficial
effects of GLP-1 releasing CellBeads on infarct size and
myocardial function after MI [26]. The in vitro experi-
ments performed in the current study indicate that the
factors released from the CellBeads are capable of reducing
cardiomyocyte apoptosis. These data provide mechanistic
insights into the functional benefit of CellBeads after MI,
observed in a pig model of MI.
Myocardial injury followingMI triggers an inflammatory
response, which initiates the formation of a collagen scar.
Levels of mRNA of genes involved in scar formation and the
ECM remodeling process were measured in porcine hearts
after MI using qRT-PCR. One week after MI, no significant
changes were observed in gene expression levels between
groups (Empty Beads, CellBead-MSC, and CellBead-MSC +
GLP-1). However, the largest increases in gene expression at
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Figure 4: Quantification of MMP2 and MMP9 mRNA levels. No significant differences were observed between MMP2 (a) and MMP9 (b)
mRNA levels within myocardium from infarct, border, and remote zones one week after MI. At four weeks after MI, increases in MMP2
(c) and MMP9 (d) mRNA levels were observed in the Empty Bead group in both infarct and border regions of pig heart after myocardial
infarction.𝑁 = 3–5 per group; however these differences were not significant.
oneweek afterMIwere in the infarct area of the control group
treated with CellBead-MSC, which was observed in all genes
tested. MSCs are known to secrete a number of molecules
that modulate collagen remodeling. Modulated expression of
these genes at one week indicates that the remodeling process
is initiated at an early stage following MI: TGF-𝛽 activates
myofibroblasts and stimulates the deposition of collagen [38],
which was observed in our model as evidenced by increased
levels of collagen I and collagen III mRNA. Increased
expression of both MMP and TIMP mRNA suggests that
remodeling of the ECM is also an ongoing process. GLP-1
appeared to negate the increase in gene expression observed
at one week, which could be explained by the previously
demonstrated anti-inflammatory effects of GLP-1 [27, 39].
CellBeads-MSC delivered to pig hearts in vivo did not
reduce infarct size whereas CellBeads-MSC-GLP-1 caused a
reduction in infarct size [28] suggesting that the synthesis of
collagen and balance of MMPs and TIMPs are finely tuned in
the remodeling process.
Four weeks following induction of MI, the significant
upregulation of genes in the infarct zone of the Beads treated
group indicates a delayed healing response and delayed
production of collagen I and collagen III for scar deposition
in the Beads treated group. In contrast, in the CellBead-
MSC and CellBead-MSC + GLP-1 treated groups, mRNA
levels were significantly lower; however gene expression was
still increased, indicating that scar formation is not fully
completed. Another study investigating the effects of MSCs
on ECM-related genes found varying results: I.V. injection of
humanMSCs into infarctedmice led to decreased fibrosis but
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Figure 5: Quantification of TGF-𝛽 mRNA levels using qRT-PCR. (a) One week after MI, all groups exhibited minor increases in mRNA
levels across all regions. (b) Four weeks after infarction, large increases in TGF-𝛽 were found in the infarct of Beads and Beads-MSC groups.
A significant increase was observed in the Empty Bead group in the border zone.𝑁 = 3–5 per group; 𝑃 < 0.05.
upregulation of MMPs and TIMPs [40], suggesting that it is
the balance of these two proteins that is an important factor
in determining the extent of scar formation. Caution with
extrapolation of these qRT-PCR is required as changes in
mRNA expression level rather than protein levels are being
observed.
AFM analysis allowed for visualization of collagen fibrils
and fibres on both molecular and macromolecular scale.
Although collagen fibrils have previously been imaged in
deparaffinized histological sections of decalcified bone and
cartilage [41], to our knowledge, our data demonstrates for
the first time that the ultrastructure of the collagen fibril
can be clearly imaged in previously paraffin embedded soft
tissues. The Beads treated group demonstrated an immature
scar phenotype comprised of thin, disorganized fibrils and
very few fibre bundles. The CellBead-MSC treated group,
however, displayed amature scar phenotype, with thick fibrils
in highly organized fibres. This correlates with the finding of
increased expression of collagen, MMPs, TIMPs, and TGF-
beta mRNA expression early after MI induction.
Fibrillar collagens are the key mediators of tensile
strength in noncalcified mammalian tissues [42] and until
recently the periodicity, and hence the molecular structure,
of collagen I fibrils was considered to vary between (e.g.,
67 nm in rat tail tendon and 64 nm in human dermis),
and not within, tissues [43]. Recent AFM based studies
performed using our tissue section AFM technique have
clearly demonstrated, however, that not only can periodicity
vary within a tissue (from 59–66 nm in ovine dermis) but
also the suprastructure of collagen fibrils is sensitive to
physiologically induced remodeling in oestrogen deprived
sheep [44, 45]. Whilst the functional implications of this
alteredmolecular structure remain to be elucidated, it is clear
that collagen fibril periodicity may be a sensitive structural
biomarker of aberrant tissue remodeling. Further studies are
required to decipher the implications of this finding and to
see if increased periodicity results in decreased scar stiffness
and therefore decreased risk of arrhythmias.
Fibril diameter has previously been used as an indication
of structural change [46, 47], with changes in diameter
associated with a number of disease states. In this study,
collagen fibril diameter was significantly increased in the
group treated with MSCs, indicating again that the factors
released from MSCs are having a profound effect on the
structure of the collagen scar that is deposited following
MI. This alteration in the structure would also suggest an
alteration in the function of the collagen scar; however
further work is required to investigate this.
5. Limitations
Due to the highly complex nature of the remodeling process
that occurs in the heart after MI, the two time points
investigated in this study (one week and four weeks after
MI) only provide a limited snap shot of the remodeling
process. Future studies should aim to investigate further the
mechanisms involved in the remodeling process following
MI and the interplay between collagen, MMPs, and TIMPs
and apoptosis in regulating this process and how this can be
modified therapeutically using MSCs
6. Summary
In summary, we have demonstrated that MSCs, either alone
or engineered to secrete GLP-1 significantly modulate the
healing response following MI. Both paracrine factors from
the MSCs and the GLP-1 demonstrated antiapoptotic actions
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Figure 6: Collagen fibril structures identified using AFM. (a) Fibre bundles from an untreated scar four weeks following MI. (b) A higher
magnification of micrograph (a) reveals more details of the individual fibrils comprising the bundle, with D-periods clearly visible. (c) D-
period length (i) and fibril width (ii) are indicated by arrows. There were a significantly increased periodicity (d), 𝑃 < 0.05, and a trend
towards increased fibril thickness (e) in MSC treated groups four weeks after MI.
on human adult cardiomyocytes early after ischaemia in vitro,
with MSCs secreting GLP-1 showing more potent effects.
Experiments performed using myocardial tissue obtained
following MI in pigs demonstrated that MSCs significantly
alter collagen scar formation shown by alterations in gene
expression of a number of genes involved in remodeling.This
resulted in changes in the myocardium after infarct compris-
ing of fibrils with a higher periodicity and increased diameter.
Furthermore we have developed a new AFM technique for
high quality imaging of paraffin embedded tissue. Further
work is required to examine whether the altered structure of
the scar is beneficial for remodeling and recovery following
MI.
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